Bristol Myers Squibb

BMY Healthcare & Pharma 5/10 Medium Risk
5/10
Sector avg: 2.8/10

Bristol Myers Squibb carries $44.8B in long-term debt, with $8.8B in scheduled principal maturities. Notably, the entire $8.8B maturity schedule falls within five years, creating a concentrated refinancing window. DebtCanary scores BMY at 5/10, indicating moderate refinancing pressure.

Maturity Schedule

Year 1 $2.0B Year 2 $2.0B Year 3 $544M Year 4 $2.2B Year 5 $2.1B Beyond 5 $0
Period Amount Due % of Total
Year 1 (0-12 months) $2.0B 22.6%
Year 2 (12-24 months) $2.0B 22.6%
Year 3 (24-36 months) $544M 6.2%
Year 4 (36-48 months) $2.2B 24.9%
Year 5 (48-60 months) $2.1B 23.7%
Beyond 5 Years N/A N/A
Total Scheduled Maturities $8.8B 100.0%

Key Metrics

Total Long-Term Debt
$44.8B
Near-Term (12mo)
$2.0B
Interest Coverage
N/A
Debt/Equity
2.43
Cash Coverage
5.10x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 22.6% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 2.43 25%
Cash Coverage of Near-Term Debt 5.10x 20%

Related Companies

Johnson & Johnson
JNJ
1/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
4/10
Debt: N/A 12mo: $3.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
1/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
3/10
Debt: $29.5B 12mo: $781M
Amgen
AMGN
6/10
Debt: $54.6B 12mo: $4.6B
Gilead Sciences
GILD
3/10
Debt: $24.9B 12mo: $2.8B
Regeneron Pharmaceuticals
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2025-12-31. Filing date: 2026-02-11. Data last fetched: 2026-03-29. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Bristol Myers Squibb →